2026 EPS consensus $4.51. Backs FY25 revenue view $1.100B-$1.115B, consensus $1.1B. “Looking ahead, for the full year, we remain committed to rebuilding long-term supply chain capacity in Clear Eyes and expect to close the Pillar5 transaction as planned. We are reaffirming our FY26 net sales outlook which anticipates eye care supply improvements in second half thanks to these long-term capacity efforts. For profitability, we are now expecting earnings per share at the higher end of our previous range as well as free cash flow of $245M or more, driven by our strong financial profile and share repurchases executed in the second quarter,” he continued.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results
- Prestige Consumer reports Q2 adjusted EPS $1.07, consensus 97c
- Prestige Consumer Healthcare (PBH) Q2 Earnings Cheat Sheet
- Prestige Consumer price target lowered to $71 from $75 at Jefferies
- Prestige Consumer price target lowered to $72 from $82 at Oppenheimer